Related Experiment Video

Updated: Aug 5, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Effectiveness of RSV Prevention Strategies in US Infants: 2024-2025

Amanda B Payne1, Steph Battan-Wraith2, Sarah E Reese2

  • 1National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Pediatrics
|August 3, 2026
PubMed

Insights

Nirsevimab and maternal RSV vaccination effectively reduced emergency department visits and hospitalizations in infants during their first RSV season. Higher uptake of these interventions improved their estimated effectiveness against severe respiratory syncytial virus disease.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Immunology

Background:

  • Two key interventions, nirsevimab (a monoclonal antibody) and maternal respiratory syncytial virus (RSV) vaccination, were recommended in the US in 2023 to protect infants from severe RSV illness.
  • Limited uptake in the 2023-2024 season hindered initial effectiveness assessments.
  • This study aimed to evaluate the effectiveness of these interventions during the 2024-2025 RSV season with anticipated higher uptake.

Purpose of the Study:

  • To estimate the effectiveness of nirsevimab and maternal RSV vaccination against RSV-associated emergency department (ED) encounters and hospitalizations in US infants.
  • To assess these interventions during the 2024-2025 RSV season, a period expected to have higher immunization rates.

Main Methods:

  • Utilized electronic health record data from five healthcare systems for test-negative analyses.
  • Included infants in their first RSV season, analyzing ED encounters and hospitalizations for RSV-like illness from October 1, 2024, to March 31, 2025.
  • Employed logistic regression models, adjusting for demographic and temporal factors, to compare RSV-positive versus RSV-negative encounters based on immunization status.

Main Results:

  • Nirsevimab demonstrated 62% effectiveness against RSV-associated ED encounters (95% CI: 54-68) and 77% effectiveness against hospitalization (95% CI: 61-87).
  • Maternal RSV vaccination showed 49% effectiveness against RSV-associated ED encounters (95% CI: 26-65) and 82% effectiveness against hospitalization (95% CI: 54-93).

Conclusions:

  • Both nirsevimab and maternal RSV vaccination proved effective in preventing RSV-associated ED encounters and hospitalizations among infants during their initial RSV season.
  • Continued monitoring of infant RSV immunization effectiveness is crucial as uptake increases and new products become available.
Abstract

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Vaccinations01:51

Vaccinations

Overview
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...